← Eichor
Study identifier: NCT07003009 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Immun Checkpoint Washout in Patients With Invasive Ductal Breast Cancer

Condition: Breast Cancer Metastatic · Breast Carcinoma  ·  Sponsor: Istanbul Training and Research Hospital

PhaseNA
Planned participants30
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

Invasive ductal carcinoma is the most common type of invasive breast cancer. In cases where axillary lymph node metastases are diagnosed through screening, they can be found in up to 25% of cases, and in symptomatic cases, up to 60% of cases. The clinical detection accuracy of axillary lymph node metastases is only 33%. Accurate staging of lymph nodes in breast cancer patients is crucial for both prognosis and treatment. Ultrasonography is much more sensitive than physical examination alone for determining axillary lymph node involvement in breast cancer staging. Fine needle aspiration biopsy or core biopsy is diagnostic in lymph nodes that cannot be clarified solely by ultrasonography or are suspicious. Although biopsy sampling yields high diagnostic rates, it requires an experienced pathologist and sometimes takes weeks to yield results. Therefore, there is a need for faster and less costly diagnostic methods for diagnosing axillary metastases. Among thyroid cancers, papillary thyroid carcinomas, a malignancy in which the lymph node washout method is used to determine lymph node metastasis, are the most common. In papillary thyroid cancer patients, washout sampling of neck lymph nodes by fine needle aspiration, searching for thyroglobulin, a protein normally found in thyroid tissue, is considered one of the most valid methods for detecting lymph node metastasis in this cancer. In recent years, immune checkpoint molecules associated with cancer have been widely used as bioma…

This description comes directly from the study's public registry record.

Talk to the study team

Ufuk Oguz Idiz, Assoc. Prof. MD. PhD  ·  +905062044714  ·  ufukidiz@gmail.com

Mert Ali Dolek, MD  ·  +905364310364  ·  mertdolek@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Istanbul Training and Research HospitalIstanbul, Turkey (Türkiye)Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07003009